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ABSTRACT
Background: We investigated the possibility of preventing common cold-like symptoms as a previously un-
known benefit of leukotriene receptor antagonists (LTRAs) .
Methods: A total of 279 adult patients with bronchial asthma referred to our hospital between June and De-
cember 2004 were retrospectively analyzed. Patients were divided into LTRA treated and untreated groups.
Frequency of acute exacerbations and number of visits to emergency rooms and of hospital admissions were
analyzed as indicators of frequency of infections and asthma exacerbation over the previous 12 months.
Results: Irrespective of inhaled corticosteroid (ICS) use, frequency of infections was significantly lower in the
LTRA treated group (0.3 ± 0.7 timesyear) than in the LTRA untreated group (1.6 ± 4.2 timesyear) (P < 0.05),
suggesting that LTRA therapy prevents common cold-like symptoms. Frequency of acute exacerbations and
number of hospital admissions were significantly lower in the LTRA treated versus LTRA untreated group (0.4 ±
0.8 versus 2.7 ± 4.3 timesyear and 0.0 ± 0.2 versus 0.4 ± 0.7 timesyear, respectively; both P < 0.01). When
the patients were divided into ICS treated and untreated groups, none of the parameters analyzed differed sig-
nificantly between the two groups, although all parameters tended to be lower in the ICS treated group.
Conclusions: Adult asthma patients undergoing treatment with LTRAs exhibit lower incidence rates of com-
mon cold-like symptoms than those not receiving LTRAs. LTRAs play an important role in reducing the inci-
dence of common cold-like symptoms among asthma patients and in suppressing exacerbation of asthma
symptoms possibly associated with these symptoms.
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INTRODUCTION
When managing patients with bronchial asthma
(hereinafter simply called asthma) in clinical practice,
physicians often encounter cases in which symptoms
of cold or flu trigger exacerbation of asthma symp-
toms. These experiences suggest that flu symptoms
(i.e. viral infections) have some impact on eosino-
philic inflammation of the airway, which is a basic fea-
ture of asthma. Involvement of viral infection in exac-
erbation of asthma has been reported in children as
well as in adults.1-3 However, although viral infection
is known as a noteworthy factor when predicting
asthma prognosis in children,4,5 less is known about
the corresponding relationship between these factors
in adult patients.6,7
Regarding the mechanism for exacerbation of
asthma following viral infection, it was recently dis-
closed that leukotrienes (LTs) produced in the airway
in response to infection play important roles in this
process.8 Thereafter, several reports were published
concerning suppression of exacerbation of asthma in-
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duced by viral infection of the airway using LT recep-
tor antagonists (LTRAs).9,10 Although there have
been reports of the possibility of preventing onset of
cold or flu in asthmatic children by LTRAs,11 our lit-
erature search identified no such reports in adults
with this disease.
Under these circumstances, we retrospectively in-
vestigated adult asthma patients attending our outpa-
tient clinic as to whether LTRAs are effective in pre-
venting common cold-like symptoms in these pa-
tients. Furthermore, the use of inhaled corticosteroid
(ICS) was also studied in this respect.
METHODS
This retrospective cohort study examined whether
LTRAs are useful in preventing common cold-like
symptoms in adult asthma patients. Subjects were all
279 asthma patients who were referred to our institu-
tion between June and December 2004. The study du-
ration was 12 months. Patients were divided into
LTRA treated and untreated groups. Of the 183 LTRA
treated patients, 68 took montelukast and 115 pranlu-
kast. At the start of the study, the following parame-
ters were analyzed and compared: peak expiratory
flow (PEF), percentage of eosinophils in peripheral
blood, serum and sputum eosinophil cationic protein
(ECP), forced expiratory volume in 1 s (FEV1.0), air-
way hyperresponsiveness (Dmin), and expired NO.
Expired NO level was measured by NO Analyzer
(280NOAi, Sievers, Boulder, CO, USA). PEF (Lmin)
was measured by Mini-Wright peak flow meter
(Clement Clarke, Essex, UK) and FEV1.0 (L) by spi-
rometer, CHESTAC-8800 (CHEST, Tokyo, Japan).
Frequency of infections and indicators of asthmatic
exacerbation including frequency of acute exacerba-
tions, number of visits to emergency rooms, and
number of hospital admissions over the 12 month pe-
riod were checked by viewing medical records of in-
dividual patients and analyzed in relation to use of
LTRAs and ICS. Based on the classification of the
Global Initiative for Asthma (GINA) 200212 a judg-
ment of acute exacerbation of asthma was made if at
least one of the following requirements was satisfied:
1) persistence of asthma symptoms for 3 days; 2)
prescription of short acting β agonist (SABA) twice
daily or more frequently; and 3) prescription of oral
steroids. Common cold-like symptoms were defined
as a condition in which at least one symptom of acute
rhinitis (rhinorrhea, nasal congestion, and sneeze) is
accompanied by symptoms of pharyngitis and lower
airway inflammation. Presence or absence of lower
airway inflammation was judged on the basis of pres-
ence or absence of sputum. Use of other anti asth-
matic drugs was not taken into account in the present
study. Written informed consent was obtained from
all patients before their medical data were accessed.
Total frequency of each event during the 12 month
period was divided by total number of patients so as
to yield annual frequencyperson. Background vari-
ables in the LTRA treated and untreated groups were
compared by chi square test and unpaired t test. The
Mann Whitney test was employed for intergroup
comparison of the frequency of each event, i.e. com-
parison between the LTRA treated and untreated
groups subdivided by use or non use of ICS and be-
tween the ICS treated and untreated groups subdi-
vided by use or non use of LTRAs.
RESULTS
When background variables before treatment were
compared between the LTRA treated and untreated
groups, no significant difference was noted in age, du-
ration of sickness, smoking history, severity of dis-
ease, and disease type (Table 1). Moreover, no sig-
nificant difference was noted in disease severity pa-
rameters (PEF, percentage of eosinophils in periph-
eral blood, serum and sputum ECP, FEV1.0, Dmin,
and expired NO) between these two groups (Table
2).
ICS was administered as the primary treatment for
asthma and LTRAs were added when ICS was not
enough to control the symptoms. Overall, the fre-
quency of infection during the 12 month period was
significantly lower in the LTRA treated than in the
LTRA untreated group (0.3 ± 0.7 versus 1.6 ± 4.2
timesyear, P < 0.05) (Fig. 1). Furthermore, when the
same parameter was analyzed among subgroups of
patients treated with and without ICS, it was signifi-
cantly lower in those receiving versus those not re-
ceiving LTRAs (0.3 ± 0.7 versus 1.3 ± 3.5 and 0.3 ± 0.6
versus 2.3 ± 6.0 timesyear, respectively; both P <
0.05) (Fig. 1).
As shown in Figure 2, frequency of acute exacerba-
tion and number of hospital admissions were signifi-
cantly lower in the LTRA treated than in the un-
treated group (acute exacerbation: 0.4 ± 0.8 versus
2.7 ± 4.3 timesyear; hospital admissions: 0.0 ± 0.2
versus 0.4 ± 0.7 timesyear; both P < 0.01). Number
of visits to emergency rooms tended to be lower in
the LTRA treated versus untreated group, although
this difference was not statistically significant (0.3 ±
0.8 versus 0.7 ± 1.6 timesyear; P = NS) (Fig. 2).
When the frequency of each of these events was ana-
lyzed in patients subdivided by use or non use of ICS,
frequency of acute exacerbation and number of hospi-
tal admissions were significantly lower and number of
visits to emergency rooms tended to be lower (i.e.,
P = NS) in the LTRA treated than untreated group ir-
respective of taking ICS (data not shown). When the
frequency of each of these events was analyzed in pa-
tients subdivided by use or non use of LTRAs, it
tended to be lower in the ICS treated than in the un-
treated group irrespective of the use or non use of
LTRAs, although this difference was not statistically
significant (data not shown).
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Table 1 Patient characteristics.
TotalLTRA (－)LTRA (＋)
27996183Total number of cases
119/16034/6285/98Sex (M/F)
52.0 ± 19.149.5 ± 18.953.3 ± 19.2Age (years)
7.1 ± 8.37.6 ± 7.36.9 ± 8.8Duration of asthma (years)
Smoking history (n)
 8630 56Curent smoker
 5118 33Ex smoker
14248 94Never smoker
Severity (n)
13244 88Step 1
 7427 47Step 2
 3413 21Step 3
 3912 27Step 4
Disease type (n)
16261101Atopic
11735 82Non atopic
Table 2 Baseline parameters of patients in the LTRA (＋) and (－) groups.
P valueLTRA (－)LTRA (＋)
NS345 ± 162369 ± 141PEF (L/min)
NS5.86 ± 4.015.71 ± 3.34Peripheral blood eosinophils (%)
NS 915 ± 1789529 ± 590IgE RIST (IU/mL)
NS19.6 ± 18.627.8 ± 10.1Serum ECP (μg/L)
NS 914 ± 11901395 ± 2489Sputum ECP (μg/L)
NS2.18 ± 0.882.41 ± 1.44FEV1.0 (L)
NS3.04 ± 4.582.32 ± 2.77Dmin (units)
NS68.4 ± 66.757.9 ± 45.1NO value (ppb)
RIST, radioimmunosorbent test; ECP, eosinophil cationic protein; FEV1.0, forced expiratory volume in 1 second.
Fig. 1 Frequency of infections during the 12 month study 
period in 279 adult asthma patients divided into LTRA 
treated and untreated groups and ICS treated and untreated 
groups. LTRA (－) ICS (＋): 24 patients, LTRA (－) ICS 
(－): 72 patients, LTRA (＋) ICS (＋): 109 patients, LTRA
(＋) ICS (－): 74 patients. The Mann Whitney test was em
ployed for intergroup comparison of the frequency of onset 
of infection. *P ＜0.05.
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DISCUSSION
Both psychological and environmental factors have
been shown to influence the onset of asthma at-
tacks.13 Among all causes, viral infection of the airway
is the most frequent precipitating factor for asthma
episodes. In particular, many data have been accumu-
lated concerning the relationship between viral infec-
tion and exacerbation of asthma in infants and chil-
dren.4,5,14 Regarding the mechanism for exacerbation
of asthma due to viruses, it was recently revealed that
LTs produced in the airway under stimulation with in-
fection play an important role. It therefore seems rea-
sonable to suppose that LTRAs, which block the LT
pathway, may be useful in suppressing exacerbation
of asthma following viral infection, and several re-
ports endorsing this view have been published.
Among animal studies, Wedde-Beer et al.9 reported
that treatment with montelukast suppresses vascular
permeability of airway mucosa in a rat model of respi-
ratory syncytial (RS) virus infection. Clinically, Bis-
gaard et al.10 reported that montelukast delays and
Horiguchi T et al.
266 Allergology International Vol 56, No3, 2007 www.jsaweb.jp
Fig. 2 Frequency of acute exacerbation of asthma symp
toms (A), visit to emergency rooms (B), and hospital admis
sion (C) in 279 adult asthma patients divided into LTRA 
treated and untreated groups and ICS treated and untreated 
groups. LTRA (－) ICS (＋): 24 patients, LTRA (－) ICS 
(－): 72 patients, LTRA (＋) ICS(＋): 109 patients, LTRA 
(＋) ICS (－): 74 patients. The Mann Whitney test was em
ployed for intergroup comparison of the frequency of onset 
of infection. *P ＜0.05, **P＜0.01.
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reduces the onset of asthmatic symptoms in children
following RS virus infection. They additionally re-
ported that in children aged 2―5 years intermittent
asthma treatment with montelukast significantly sup-
presses the incidence of acute exacerbation of
asthma following viral infection in comparison with
placebo.11 It has been suggested that viral infection in
infants and children, particularly those with severe
bronchiolitis requiring hospitalization, serves not
only as a factor precipitating attacks of asthma imme-
diately after infection but also as a risk factor for per-
sistence of asthma or recurrent wheeze lasting >10
years.4,5,14 Hence it seems natural that the results of
montelukast therapy in children are attracting close
attention. To date, however, very few reports have
been published concerning the effects of this drug in
adult asthma patients. Regarding LTRAs, discussions
have been made not only on their effects against ex-
acerbation of asthma following viral infection but also
in preventing viral infection itself. Concerning the lat-
ter possibility, Bisgaard et al.11 reported that the inci-
dence of cold or flu among children with intermittent
asthma was reduced by 29% following montelukast
therapy. On the other hand, van Adelsberg et al.15 re-
ported that in a study designed to evaluate the safety
of montelukast in infants with asthma aged 6―24
months and in patients presenting with asthma-like
symptoms, the incidence of upper airway infection
was 32% in the montelukast treatment group and 21%
in the placebo group. Thus no clear cut results have
been obtained concerning the effect of LTRAs in pre-
venting viral infection. Moreover, in some reports
that have suggested the possibility of preventing viral
infection by LTRAs, the mechanism of action was not
clearly demonstrated.
In the present study, emphasis was placed on as-
sessing the possibility of preventing common cold-
like symptoms in adults using LTRAs. Retrospec-
tively assessing the medical records of patients man-
aged at our facility, we observed that the frequency of
infection was significantly lower in those taking ver-
sus not taking LTRAs irrespective of whether they
concomitantly used ICS. Possible mechanisms ex-
plaining this effect of LTRAs include: 1) direct effect
on cells by suppressing infection; 2) indirect effect
such as normalization of airway function and reduc-
tion of receptor expression needed for viral infection
of airway epithelium. On the basis of our results, it is
plausible to estimate that treatment with LTRAs re-
duces the frequency of asthmatic attacks over long
time periods, stimulating normalization of airway epi-
thelium and resumption of foreign body eliminating
function (ciliary movement etc.) and thus indirectly
suppressing common cold-like symptoms. It was re-
cently reported that LTRAs act on dendrocytes and
suppress Th2 reactions in mice.16 It seems likely that
normalization of airway epithelium is mediated not
only by suppression of LTs’ action in inflammatory re-
action but also by control of more upstream immune
reactions. Another possible mechanism for indirect
suppression of infection by LTRAs is lowering expres-
sion of cellular receptors for infecting viruses. For in-
LTRAs Reduce Common Cold-like Symptoms in Asthma
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stance, intercellular adhesion molecule (ICAM)-1,
which is upregulated following major rhinovirus in-
fection, acts as a receptor for this pathogen and
serves as adhesion molecule for inflammatory cell in-
filtration.17-19 Although there are no reports on the ef-
fect of montelukast in suppressing upregulation of
ICAM-1 after rhinovirus infection, it is known that
this agent significantly reduces expression of soluble
ICAM-1 in asthma patients.20 It seems probable that
these actions of LTRAs reduce the susceptibility of
asthma patients to viral infections. Regarding direct
action of LTRAs in suppressing viral infection, the
present study yielded no results in support of such
action. This issue remains open for future research.
In the present study, many events (acute exacerba-
tion, visit to emergency rooms, and hospital admis-
sion) took place within 1 week after common cold-
like symptoms (data not shown). These events there-
fore seem associated with infection. As stated above,
most previous reports on exacerbation of asthmatic
symptoms following infection pertain to children. In
this respect, our results obtained in adults (particu-
larly the results of drug therapy) can be deemed valu-
able. Considering that LTRAs may reduce onset of in-
fection and suppress postinfection exacerbation of
asthmatic symptoms, it seems possible that LTRAs
may be indicated for the prevention and suppression
of common cold-like symptoms and post infection ex-
acerbation of asthma as well as suppression of the
loop of exacerbation (increased susceptibility to infec-
tion due to deterioration of airway condition).
We have shown that treatment with ICS alone has
a tendency to suppress asthmatic events, but this is
nonsignificant. It seems likely that for prevention of
common cold-like symptoms and suppression of ex-
acerbation of asthma following viral infection, com-
bined use of ICS and LTRAs may be more useful than
use of either drug alone.
CONCLUSION
The present study confirms that LTRAs can prevent
common cold-like symptoms and suppress infection-
associated exacerbation of asthma in adult patients
with this disease. ICS are currently used as anti-
inflammatory agents of first choice when dealing with
chronic airway inflammation. The results of the pre-
sent study suggest that LTRAs, by preventing com-
mon cold-like symptoms in adult asthma patients,
could provide a very useful means of controlling
asthma.
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